Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients. (TOPIRAMATEPTSD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008 by Federal University of São Paulo.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Information provided by:
Federal University of São Paulo
ClinicalTrials.gov Identifier:
NCT00725920
First received: July 28, 2008
Last updated: January 27, 2009
Last verified: January 2008
  Purpose

The study is 12-week randomized placebo controlled trial compared to topiramate to treat patients with posttraumatic stress disorder, according to DSM-IV criteria.

Patients will receive topiramate or placebo, the dose will start with 25 mg/day and every week 25mg will be increment according to patients tolerance to side effects.

Patients will be evaluated by blind raters using CAPS, BDI, BAI, SF-36 and SAS. the outcomes will be improvement on PTSD, Depression, Anxiety, quality of life and social adjustment scale according to scales above.


Condition Intervention Phase
Posttraumatic Stress Disorder
Drug: topiramate
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Clinical Trial to Study the Topiramate Efficacy for Posttraumatic Disorder Treatment

Resource links provided by NLM:


Further study details as provided by Federal University of São Paulo:

Primary Outcome Measures:
  • Clinician Administered Posttraumatic Stress Disorder Scale [ Time Frame: 12 week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • SF-36 [ Time Frame: 12 week ] [ Designated as safety issue: No ]

Estimated Enrollment: 72
Study Start Date: January 2007
Estimated Study Completion Date: July 2009
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
patients receiving the active drug: topiramate
Drug: topiramate
patients will receive the active drug
Placebo Comparator: 2 Drug: placebo
initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerancy and no response dose could be up to 200 mg day

Detailed Description:

Seventy-two (72) patients will be randomly allocated, in a stratified manner, according to sex and comorbidity with depression, into two (2) groups: topiramate and routine clinical follow-up, and a group that would receive placebo pills and routine clinical follow-up. The patients will be submitted to evaluations by trained independent researchers, who will apply a structured clinical interview for DSM-IV in order to evaluate the presence of psychiatric disorders (SCID I and SCID-II); the scale of evaluation of the Impact Event Scale-IES; the frequency and intensity of the symptoms of PTSD and of the variations associated with the trauma (PTSD Scale administered by clinical personnel: "Clinician-Administered PTSD Scale" - CAPS); severity of depression: Beck Depression Inventory (BDI) and that of anxiety: Beck Anxiety Inventory (BAI); a scale for the evaluation of social adaptation: Social Adjustment Scale (SAS); a scale for the evaluation of Quality of Life: SF-36; a scale for the evaluation of global functioning - axis V of DSM-IV (AGF). The patients will receive active treatment for twelve (12) weeks. After this period, the patients who have been using topiramate and who have had an improvement in their clinical condition will continue to receive further treatment for another twelve (12) weeks. Patients will have their medication suspended after twenty four (24) weeks and will be followed-up for a further twenty four (24) weeks. Patients from the placebo group who showed improvement will continue to receive clinical follow-up for a further thirty six (36) weeks. Patients from the placebo group who showed a worsening in their clinical status, evaluated through the CGI, will be excluded from the study and sent for traditional treatment at the PROVE (Violence and Stress Program) clinic. Patients who terminated the active phase of the study who did not obtain a clinical improvement will be sent for traditional treatment at the PROVE clinic. The principal outcomes to be examined will be: Response (a decrease of 50% in the CAPS score starting from the baseline) and remission (lack of diagnostic criteria for PTSD in the CAPS). After the end of the treatment, the collected data will be tabulated and compared using parametric and non-parametric tests. In this study the validation of the CAPS scale for Portuguese will be carried out.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Outpatient, male and female 18 to 60 yrs old
  • PTSD diagnostic according to DSM-IV criteria
  • Patients who agree to receive diagnostic after SCID I application by a trained psychiatrist
  • Sexually active female patients who agree to use contraceptive
  • Patients who agree to sign the IRB approved informed consent

Exclusion Criteria:

  • Patients who have schizophrenic disorder, delusional, psychotic depression, schizo-affective, bipolar and dependence to psychoactive substance disorders
  • Patients who have clinical disorders not compensated, which require clinical treatment as priority
  • Pregnancy
  • Previous renal calculosis history
  • Being under antidepressant, or other psychotropic medications
  • BMI under 20.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00725920

Contacts
Contact: Marcelo F Mello, MD 55 11 30786829 mf-mello@uol.com.br
Contact: Mary S Yeh, MD 55 11 55494374 wmary@ig.com.br

Locations
Brazil
Federal University of Sao Paulo Recruiting
Sao Paulo, Brazil, 04023-061
Contact: Mary S Yeh, MD    55 11 55 49 43 74    wmary@ig.com.br   
Contact: Marcelo F Mello, MD    55 11 30786829    mf-mello@uol.com.br   
Sub-Investigator: Mary S Yeh, wmary@ig.com.br         
Sponsors and Collaborators
Federal University of São Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo
Investigators
Principal Investigator: Marcelo F Mello, MD Federal University of São Paulo
  More Information

No publications provided by Federal University of São Paulo

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Marcelo Feijo de Mello, UNIFESP
ClinicalTrials.gov Identifier: NCT00725920     History of Changes
Other Study ID Numbers: FAPESPTopiramatePTSD
Study First Received: July 28, 2008
Last Updated: January 27, 2009
Health Authority: Brazil: National Committee of Ethics in Research

Keywords provided by Federal University of São Paulo:
PTSD,
posttraumatic
stress
disorder,
randomization,
placebo,
controlled

Additional relevant MeSH terms:
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Anxiety Disorders
Mental Disorders
Topiramate
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Anti-Obesity Agents

ClinicalTrials.gov processed this record on April 17, 2014